What is the official website of Zoetis ?

The official website of Zoetis is http://www.zoetis.com.

What is Zoetis's cybersecurity risk score?

Zoetis has an AI-generated cybersecurity risk score of 813 out of 1000, indicating a Good security posture according to Rankiteo's assessment.

How many security incidents has Zoetis experienced?

According to Rankiteo, Zoetis currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Zoetis been affected by any supply chain cyber incidents ?

According to Rankiteo, Zoetis has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Zoetis have SOC 2 Type 1 certification ?

According to Rankiteo, Zoetis is not certified under SOC 2 Type 1.

Does Zoetis have SOC 2 Type 2 certification ?

According to Rankiteo, Zoetis does not hold a SOC 2 Type 2 certification.

Does Zoetis comply with GDPR ?

According to Rankiteo, Zoetis is not listed as GDPR compliant.

Does Zoetis have PCI DSS certification ?

According to Rankiteo, Zoetis does not currently maintain PCI DSS compliance.

Does Zoetis comply with HIPAA ?

According to Rankiteo, Zoetis is not compliant with HIPAA regulations.

Does Zoetis have ISO 27001 certification ?

According to Rankiteo,Zoetis is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Zoetis operate in ?

Zoetis operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Zoetis have ?

Zoetis employs approximately 12,134 people worldwide.

Does Zoetis own any subsidiaries ?

Zoetis presently has no subsidiaries across any sectors.

How many LinkedIn followers does Zoetis have ?

Zoetis's official LinkedIn profile has approximately 576,885 followers.

What is the NAICS classification code for Zoetis ?

Zoetis is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Zoetis have a Crunchbase profile ?

No, Zoetis does not have a profile on Crunchbase.

Does Zoetis have a LinkedIn profile ?

Yes, Zoetis maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/zoetis.

How many cybersecurity incidents has Zoetis experienced ?

As of June 12, 2026, Rankiteo reports that Zoetis has not experienced any cybersecurity incidents.

How many peer or competitor companies does Zoetis have ?

Zoetis has an estimated 5,686 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Zoetis

Boost Score +25 with badge (5 left)

813

/1000

Good

838

/1000

Good

Zoetis Vendor Cyber Rating & Cyber Score

zoetis.com

Add Your Compliance Badge

The world’s leading animal health company. We’ve been innovating ways to predict, prevent, detect, and treat animal illness for over 70 years, and we continue to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers. Our leading portfolio and pipeline makes a difference in over 100 countries. Community Guidelines: This page is intended to share how Zoetis is advancing care for animals. We aspire to create a supportive community, but there are guidelines to which posts and comments on this page must adhere. If your post references a side effect related to any Zoetis product, we may contact you for more information. To monitor the safety of Zoetis products, we advise you to call

Zoetis A.I CyberSecurity Scoring

Scoring History

Zoetis

Zoetis CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

Zoetis Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Zoetis

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Zoetis in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Zoetis in 2026.

Incident Types Zoetis vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Zoetis in 2026.

Incident History - Zoetis (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Zoetis Subsidiaries

Parent Company

Zoetis

Pharmaceutical Manufacturing

Website: http://www.zoetis.com

Company Size: 10,000+ employees

No subsidiary data available for this company.

Loading…

Zoetis Similar Companies

MENARINI Group

menarini.com

The Menarini Group is a leading international pharmaceutical and diagnostics company, present in 140 countries worldwide, with a turnover of 4,37 Billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, infectious diseases, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants, which produce over 609 million packets of product a year and distribute them to five continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com For reading our Netiquette, please visit https://www.menarini.com/en-us/data-privacy/netiquette-of-menarini-group For reading our Privacy Notice for social networks users, please visit https://www.menarini.com/en-us/data-privacy/privacy-notice-for-social-network-users-of-menarini-group

Torrent Pharmaceuticals Ltd

cb torrentpharma.com

Torrent Pharma, with annual revenues of more than Rs 10,700 crores, is the flagship Company of the Torrent Group, with group revenues of Rs 41,000 crores. It is ranked 5th in the Indian Pharma Market and is among the Top 5 in the therapeutic segments of Cardiovascular (CV), Central Nervous System (CNS), Gastro-intestinal (GI), Vitamins Minerals Nutritionals (VMN) and Cosmo-Dermatology. The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments. Torrent has 8 manufacturing facilities , of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing around 800 scientists. The acquisition of Elder Pharma's Indian branded business in 2013, Dermaceuticals business of Zyg Pharma in 2015, API plant of Glochem Industries in 2016, Women healthcare brands from Novartis and Unichem's Indian branded business along with its Sikkim Plant in 2017 strengthened Torrent Pharma's position in the Indian Pharma market. Torrent Pharma started international acquisitions in 2005 with entry into the German market. Today, the Company has presence in more than 50 countries and is ranked No. 1 among the Indian pharma Companies in Brazil and Germany. Torrent Pharma is committed towards “not just healthcare but lifecare.”

Johnson & Johnson Innovative Medicine

cb jnj.com

At Johnson & Johnson Innovative Medicine, we innovate with purpose, to lead where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently address the most complex diseases of our time and develop the potential medicines of tomorrow. We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way. https://bit.ly/3reuMvK

Novo Nordisk

novonordisk.com

We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. Our unordinary mindset is at the heart of everything we do. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 77,000 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to block and remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html

MANKIND PHARMA LTD

mankindpharma.com

Mankind Pharma, one of the top 5 leading pharmaceutical companies in India, started its journey in 1995. Today, we have an employee base of over 20,000 and are racing towards $1 Billion. At Mankind, we aspire to aid the community in leading a healthy life by formulating, developing, commercializing, and delivering affordable and accessible medicines that satisfy urgent medical needs. We take great pride in the success of our products ranging from Pharma, OTC and FMCG brands like Manforce Condoms, Manforce Tablets, Manforce Staylong Gel, Unwanted 72, Prega News, Gas-O-Fast, Kaloree 1, Kabzend, Acne Star Gel and many others. Our operations are in 34 overseas destinations across Asia, Africa, South-East Asia, Gulf countries and CIS countries. Our Vision - To be a global pharmaceutical company, most admired for its Affordability, Quality and Accessibility of products. Our Mission - To be able to provide cost-effective, innovation based superior quality pharmaceutical products across the globe, to improve the lives of the patients. Mankind strongly believes and follows its Core Values: 𝐂𝐮𝐬𝐭𝐨𝐦𝐞𝐫 𝐂𝐞𝐧𝐭𝐫𝐢𝐜𝐢𝐭𝐲: Commitment to Customer - Internal and External 𝐐𝐮𝐚𝐥𝐢𝐭𝐲: It is in our DNA to maintain and deliver highest quality standards and products 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: Intensely Research driven organization aiming at product innovation and technology improvements 𝐈𝐧𝐭𝐞𝐠𝐫𝐢𝐭𝐲: Always trustworthy, widely respected to be honest, and believed by everyone 𝐆𝐨 𝐁𝐞𝐲𝐨𝐧𝐝: Aim higher than capabilities 𝐏𝐞𝐨𝐩𝐥𝐞 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧: Together we are foreseeing future and diligently stimulating our people in attaining goals

Dr. Reddy's Laboratories

drreddys.com

Established in 1984, we are a global pharmaceutical company headquartered in Hyderabad, India. Driven by our purpose of ‘Good Health Can’t Wait’, we work to provide access to affordable and innovative medicines. We offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major markets include USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in future growth drivers such as access to novel molecules, digital therapeutics and consumer healthcare. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com. Caution Notice: Dr. Reddy's has been made aware of candidates receiving fraudulent job opportunities from unauthorised recruiting agencies or people impersonating Dr. Reddy's leaders. These fraudulent jobs may be advertised on employment sites or mimic our careers site and company email addresses. Please know that Dr. Reddy's Laboratories has no affiliation or connection to these situations. Dr. Reddy's (and its associated/group companies) follows a formal recruitment process through its own HR department. Please report immediately in case you suspect a fraudulent job. You may raise your concern by: Accessing https://drreddys.ethicspoint.com. Calling on the hotline number. List of hotline numbers are available in https://drreddys.ethicspoint.com. The hotline is available 24x7 in multiple languages. Writing to [email protected] or [email protected]. For our community guidelines on LinkedIn, please visit: https://shorturl.at/LTvNZ

Astellas Pharma

astellas.com

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines

AUROBINDO PHARMA LTD

aurobindo.com

Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and markets a wide range of generic pharmaceuticals, branded specialty drugs, and active pharmaceutical ingredients (APIs) across more than 150 countries. It is ranked among the top 10 generic companies in eight European nations and holds the distinction of being the largest generic pharmaceutical company in the United States. With over 30 state-of-the-art manufacturing and packaging facilities approved by leading global regulatory authorities including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA, Aurobindo Pharma ensures the highest standards of quality. Its robust portfolio spans eight major therapeutic areas: Central Nervous System (CNS), Antiretroviral (ARV), Cardiovascular (CVS), Antibiotics, Gastroenterology, Anti-diabetics, Oncology, and Dermatology, supported by a strong R&D infrastructure that drives innovation, affordability, and accessibility.

Sandoz

sandoz.com

Sandoz is the global leader in generic and biosimilar medicines. Our Purpose is to pioneer access to medicines for patients globally. We are on a mission to drive innovation in the healthcare industry by freeing up resources sustainably and responsibly while continuing to address global health challenges such as antimicrobial resistance. We are present in more than 100 countries and our medicines serve some 500 million people every year. We have two main global businesses: Generics - divided between standard generics and complex generics - and Biosimilars. Read our community engagement guidelines: http://bit.ly/4ofoggc

Loading…

NEWS

Zoetis CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

April 03, 2026 06:59 AM

Zscaler Stock After Earnings: Can This Cyber Name Keep Outgrowing the Nasdaq?

Zscaler just dropped fresh earnings and guidance that jolted the cyber trade, but the market reaction was anything but simple.

Read Article

October 01, 2025 07:00 AM

Cybersecurity Awareness Month: Oklahoma’s commitment to a safer digital future

In a joint effort with the Office of Management and Enterprise Services (OMES), Gov. J. Kevin Stitt has declared October 2025 as...

Read Article

October 01, 2025 07:00 AM

Zoetis Receives Conditional Approval for Dectomax®-CA1 Injectable for the Prevention and Treatment of New World Screwworm Myiasis in Cattle

Zoetis announced today that Dectomax®-CA1 Injectable is the first and only parasite control product to receive conditional approval from the...

Read Article

September 19, 2025 07:00 AM

Tata Communications Limited lauded at Asian Technology Excellence Awards 2025 for SIEM-led transformation

Cyber resilience transformation with Kotak Mahindra Asset Management Company earns recognition.

Read Article

June 27, 2025 07:00 AM

Animal health company Zoetis signs consulting deal with Infosys

Infosys, an India-based IT consulting firm, has won a consulting contract with Zoetis, an American drug company focusing on pets and livestock.

Read Article

April 23, 2025 07:00 AM

Infosys buys Australian IT consultancy The Missing Link for $98 million

Global technology consultancy Infosys has forked out almost $100 million for Sydney-headquartered cyber solutions and consulting firm The...

Read Article

March 21, 2025 07:00 AM

PNB brings home top honours at Malaysia Technology Excellence Awards 2025

Programme HIMAYA highlights the group's commitment to maintaining robust cybersecurity measures and protecting investors and stakeholders.

Read Article

March 07, 2024 08:00 AM

Thailand cybersecurity job market sees 15% growth in 10 years

The cybersecurity job market in Thailand is expected to see a robust growth of 15% over the next decade, hence the need for specialized skills.

Read Article

July 21, 2023 07:00 AM

Zoetis IT Leader Wafaa Mamilli: ‘Play Offense’

Wafaa Mamilli holds an array of impressive titles at Fortune 500 animal health company Zoetis, including executive vice president, chief digital and technology...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-47238

SUMMARY

ClipBucket v5 is an open source video sharing platform. Prior to version 5.5.3 - #133, a normal authenticated user can edit another user's video subtitles because of a lack of authorization. They can upload subtitles, edit their name or delete them. This issue has been patched in version 5.5.3 - #133.

Published

Date2026-06-11

Updated

Date2026-06-11

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:L/A:L

Impact Score

2.5

Exploitability

3.9

REFERENCES

https://github.com/MacWarrior/clipbucket-v5/security/advisories/GHSA-x468-whmw-c863

CVE-2026-45418

SUMMARY

ClipBucket v5 is an open source video sharing platform. Prior to version 5.5.3 - #132, any authenticated user who can upload videos can add multiple subtitles from different files and change their title (English, Spanish...). The POST /actions/subtitle_edit.php request used to change their title includes a number parameter which is vulnerable to SQL Injection. A boolean-based blind SQL injection can be used to exfiltrate sensitive data. This issue has been patched in version 5.5.3 - #132.

Published

Date2026-06-11

Updated

Date2026-06-11

RISK INFORMATION (Score: 8.8)

cvss3

Base Score: 8.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H

Impact Score

5.9

Exploitability

2.8

REFERENCES

https://github.com/MacWarrior/clipbucket-v5/security/advisories/GHSA-q233-m544-6jqr

CVE-2026-45060

SUMMARY

ClipBucket v5 is an open source video sharing platform. Prior to version 5.5.3 - #129, the actions/progress_video.php endpoint is vulnerable to blind SQL injection. Any unauthenticated user can exploit the ids parameter to execute SQL queries and exfiltrate sensitive data. This issue has been patched in version 5.5.3 - #129.

Published

Date2026-06-11

Updated

Date2026-06-11

RISK INFORMATION (Score: 9.8)

cvss3

Base Score: 9.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H

Impact Score

5.9

Exploitability

3.9

REFERENCES

https://github.com/MacWarrior/clipbucket-v5/security/advisories/GHSA-wpq3-gxx7-c76h

CVE-2026-42846

SUMMARY

ClipBucket v5 is an open source video sharing platform. Prior to version 5.5.3 - #140, ClipBucket's Remote Play feature allows any authenticated user to add a video by importing an external URL as the source. Some shell commands are run with the URL as a parameter. The URL is concatenated directly into shell commands without escaping then executed, so any shell metacharacter in the URL is interpreted. This results in arbitrary command execution. This issue has been patched in version 5.5.3 - #140.

Published

Date2026-06-11

Updated

Date2026-06-11

RISK INFORMATION (Score: 9.8)

cvss3

Base Score: 9.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H

Impact Score

5.9

Exploitability

3.9

REFERENCES

https://github.com/MacWarrior/clipbucket-v5/security/advisories/GHSA-hvfx-hxmr-28c7

CVE-2026-6250

SUMMARY

An authenticated format string vulnerability exists in the ONVIF service of Tapo C110 v2 due to improper handling of user-controlled input. Externally controlled data is interpreted as a format string, which can be used to manipulate stack memory, including control flow data such as return addresses. A remote authenticated attacker may redirect execution flow to existing internal functions, triggering an unauthorized factory reset, leading to loss of configuration, deletion of stored credentials and service disruption.

Published

Date2026-06-11

Updated

Date2026-06-11

RISK INFORMATION (Score: )

cvss4

Base Score: 7.0

Complexity: LOW

CVSS:4.0/AV:A/AC:L/AT:N/PR:L/UI:N/VC:N/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…